Physician profile
Michael Curley
NPI 1184698003
$2,079.79
in general payments reported to CMS, 2019-2025
28 companies · $14.32 in 2025
The $14.32 reported for 2025 was less than what a typical Adult Medicine provider received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151 · 2020: $442 · 2021: $548 · 2022: $232 · 2023: $445 · 2024: $247 · 2025: $14.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $706.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $706.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $243.35 | 2019-2024 | Otezla, Repatha |
| Abbvie INC. | $218.58 | 2021-2024 | Vraylar |
| Pfizer INC. | $213.12 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $202.24 | 2019-2022 | |
| Novo Nordisk INC | $160.57 | 2019-2024 | Wegovy |
| Lilly USA, LLC | $151.27 | 2020-2024 | Trulicity, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $133.88 | 2020-2024 | Arexvy |
| Biohaven Pharmaceuticals, INC. | $129.36 | 2020-2021 | |
| Nevro Corp. | $114.33 | 2023 | Senza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.87 | 2023-2024 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $43.23 | 2020 | |
| Eisai INC. | $41.58 | 2020-2021 | |
| Astellas Pharma US INC | $40.00 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $38.96 | 2022 | |
| Allergan, INC. | $30.05 | 2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $29.19 | 2023 | |
| Tempus Ai, INC | $28.86 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $23.05 | 2023 | Austedo |
| Abbott Laboratories | $22.90 | 2022 | |
| Horizon Therapeutics Plc | $20.85 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $19.19 | 2022 | |
| Biotronik INC. | $18.46 | 2023 | Edora 8 Dr-T, Biomonitor, Rivacor 7 Dr-T |
| Daiichi Sankyo INC. | $17.57 | 2020 | |
| Arbor Pharmaceuticals, INC. | $15.04 | 2021 | |
| Idorsia Pharmaceuticals US INC | $14.90 | 2024 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.80 | 2019 | |
| Merck Sharp & Dohme LLC | $14.32 | 2025 | Capvaxive, Gardasil 9 |
| Astrazeneca Pharmaceuticals LP | $11.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Curley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.